PGPeter Grell

Peter Grell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter Grell has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandr Poprach

    Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic

    1 shared publication
  • Barbora Vavrusakova

    Research Center for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic

    1 shared publication
  • Igor Kiss

    Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic

    1 shared publication
  • Iveta Selingerova

    Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic

    1 shared publication
  • Jan Podhorec

    Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic

    1 shared publication
  • Jiri Nevrlka

    Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

    1 shared publication

Latest Publications

  • Open Access

    Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer

    by Simona Borilova, Peter Grell, Iveta Selingerova, Lenka Gescheidtova, Marie Mlnarikova, Ondrej Bilek, Radek Lakomy, Alexandr Poprach, Jan Podhorec, Igor Kiss, et al.

    Immune checkpoint inhibitors (ICIs), including those targeting PD-1, are currently used in a wide range of tumors, but only 20–40% of patients achieve clinical benefit. The objective of our study was to find predictive peripheral blood-based biomarkers for ICI treatment. In 41 patients with advanced malignant melanoma (MM) and NSCLC treated with PD-1 inhibitors, we analyzed peripheral blood-based immune subsets by flow cytometry before treatment initialization and the second therapy dose. Specifically, we assessed basic blood differential count, overall T cells and their subgroups, B cells, and myeloid-derived suppressor cells (MDSC). In detail, CD4 + and CD8 + T cells were assessed according to their subtypes, such as central memory T cells (TCM), effector memory T cells (TEM), and naïve T cells (TN). Furthermore, we also evaluated the predictive value of CD28 and ICOS/CD278 co-expression on T cells. Patients who achieved disease control on ICIs had a significantly lower baseline proportion of CD4 + TEM (p = 0.013) and tended to have a higher baseline proportion of CD4 + TCM (p = 0.059). ICI therapy-induced increase in Treg count (p = 0.012) and the proportion of CD4 + TN (p = 0.008) and CD28 + ICOS- T cells (p = 0.012) was associated with disease control. Patients with a high baseline proportion of CD4 + TCM and a low baseline proportion of CD4 + TEM showed significantly longer PFS (p = 0.011, HR 2.6 and p ˂ 0.001, HR 0.23, respectively) and longer OS (p = 0.002, HR 3.75 and p ˂ 0.001, HR 0.15, respectively). Before the second dose, the high proportion of CD28 + ICOS- T cells after ICI therapy initiation was significantly associated with prolonged PFS (p = 0.017, HR 2.51) and OS (p = 0.030, HR 2.69). Also, a high Treg count after 2 weeks of ICI treatment was associated with significantly prolonged PFS (p = 0.016, HR 2.33). In summary, our findings suggest that CD4 + TEM and TCM baselines and an early increase in the Treg count induced by PD-1 inhibitors and the proportion of CD28 + ICOS- T cells may be useful in predicting the response in NSCLC and MM patients.